Oncologists Cheer Melanoma Data That Tanked Moderna’s Shares
Published . Updated .
Covered by 2 outlets: The Spokesman-Review, Bloomberg.
Who covered it: Center 1 · Not rated 1. How we rate outlets
Leaked data from Moderna Inc. and Merck & Co.’s highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. Normally results of such pivotal drug studies are binary, with doctors
Directly affected
Indirectly affected
- No related companies are mapped for this report yet.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| MRNA | +7.22% | +19.41% | base | -2.35% | after close | after close | after close |
| MRK | -1.16% | +3.17% | base | — | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Oncologists cheer melanoma data that tanked Moderna’s shares The Spokesman-Review
Source: The Spokesman-Review
This story
| Company | When | Move | Status |
|---|---|---|---|
| GLD | that day | -0.70% | final price |
| GLD | three days earlier | +2.33% | final price |
| GLD | five days earlier | +3.51% | final price |
| MRK | three days earlier | +3.17% | final price |
| MRK | five days earlier | -1.16% | final price |
| MRNA | that day | -2.35% | final price |
| MRNA | three days earlier | +19.41% | final price |
| MRNA | five days earlier | +7.22% | final price |
| QQQ | that day | -0.02% | final price |
| QQQ | three days earlier | +1.80% | final price |
| QQQ | five days earlier | +0.75% | final price |
| SPY | that day | -0.48% | final price |
| SPY | three days earlier | +0.66% | final price |
| SPY | five days earlier | -0.09% | final price |
| TLT | that day | -0.53% | final price |
| TLT | three days earlier | -1.97% | final price |
| TLT | five days earlier | -2.07% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Maria Elvira Salazar sold Moderna (MRNA), worth $1,001 - $15,000 on 24 Sep 2026. That is 29 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Moderna (MRNA) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 49 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Moderna (MRNA), worth $1,001 - $15,000 on 28 Aug 2026. That is 56 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 29 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 65 days before publication. Filed 9 Sep 2026. View the filing.
- Donald J Trump, an executive branch official, sold Merck (MRK), worth $250,001 - $500,000 on 31 Jul 2026. That is 84 days before publication. Filed 22 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Oncologists Cheer Melanoma Data That Tanked Moderna’s Shares” looks
25 out of 100
“Oncologists Cheer Melanoma Data That Tanked Moderna’s Shares” scores 25 out of 100. The score uses 2 sources.